147 related articles for article (PubMed ID: 32881892)
21. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
[TBL] [Abstract][Full Text] [Related]
22. Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.
Pedersen EA; Menon R; Bailey KM; Thomas DG; Van Noord RA; Tran J; Wang H; Qu PP; Hoering A; Fearon ER; Chugh R; Lawlor ER
Cancer Res; 2016 Sep; 76(17):5040-53. PubMed ID: 27364557
[TBL] [Abstract][Full Text] [Related]
23. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
24. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
25. Microsatellites are EWS/FLI response elements: genomic "junk" is EWS/FLI's treasure.
Gangwal K; Lessnick SL
Cell Cycle; 2008 Oct; 7(20):3127-32. PubMed ID: 18927503
[TBL] [Abstract][Full Text] [Related]
26. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth.
Johnson KM; Mahler NR; Saund RS; Theisen ER; Taslim C; Callender NW; Crow JC; Miller KR; Lessnick SL
Proc Natl Acad Sci U S A; 2017 Sep; 114(37):9870-9875. PubMed ID: 28847958
[TBL] [Abstract][Full Text] [Related]
27. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
[TBL] [Abstract][Full Text] [Related]
28. Ewing's sarcoma: analysis of single nucleotide polymorphism in the EWS gene.
Silva DS; Sawitzki FR; De Toni EC; Graebin P; Picanco JB; Abujamra AL; de Farias CB; Roesler R; Brunetto AL; Alho CS
Gene; 2012 Nov; 509(2):263-6. PubMed ID: 22925827
[TBL] [Abstract][Full Text] [Related]
29. Extensive Ethnic Variation and Linkage Disequilibrium at the
Nagelkerke SQ; Tacke CE; Breunis WB; Tanck MWT; Geissler J; Png E; Hoang LT; van der Heijden J; Naim ANM; Yeung RSM; Levin ML; Wright VJ; Burgner DP; Ponsonby AL; Ellis JA; Cimaz R; Shimizu C; Burns JC; Fijnvandraat K; van der Schoot CE; van den Berg TK; de Boer M; Davila S; Hibberd ML; Kuijpers TW;
Front Immunol; 2019; 10():185. PubMed ID: 30949161
[TBL] [Abstract][Full Text] [Related]
30. Targeted sequencing of Parkinson's disease loci genes highlights SYT11, FGF20 and other associations.
Rudakou U; Yu E; Krohn L; Ruskey JA; Asayesh F; Dauvilliers Y; Spiegelman D; Greenbaum L; Fahn S; Waters CH; Dupré N; Rouleau GA; Hassin-Baer S; Fon EA; Alcalay RN; Gan-Or Z
Brain; 2021 Mar; 144(2):462-472. PubMed ID: 33349842
[TBL] [Abstract][Full Text] [Related]
31. [Functional genomics of Ewing sarcoma].
Grünewald TGP
Pathologe; 2017 Nov; 38(Suppl 2):198-201. PubMed ID: 28849372
[TBL] [Abstract][Full Text] [Related]
32. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
33. The clinical heterogeneity of round cell sarcomas with EWSR1/FUS gene fusions: Impact of gene fusion type on clinical features and outcome.
Tsuda Y; Zhang L; Meyers P; Tap WD; Healey JH; Antonescu CR
Genes Chromosomes Cancer; 2020 Sep; 59(9):525-534. PubMed ID: 32362012
[TBL] [Abstract][Full Text] [Related]
34. Rare coding variants and breast cancer risk: evaluation of susceptibility Loci identified in genome-wide association studies.
Zhang Y; Long J; Lu W; Shu XO; Cai Q; Zheng Y; Li C; Li B; Gao YT; Zheng W
Cancer Epidemiol Biomarkers Prev; 2014 Apr; 23(4):622-8. PubMed ID: 24470074
[TBL] [Abstract][Full Text] [Related]
35. Multiple chromosomal mechanisms generate an EWS/FLI1 or an EWS/ERG fusion gene in Ewing tumors.
Desmaze C; Brizard F; Turc-Carel C; Melot T; Delattre O; Thomas G; Aurias A
Cancer Genet Cytogenet; 1997 Aug; 97(1):12-9. PubMed ID: 9242212
[TBL] [Abstract][Full Text] [Related]
36. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
[TBL] [Abstract][Full Text] [Related]
37. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma.
Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M
Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178
[TBL] [Abstract][Full Text] [Related]
38. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional Programs Define Intratumoral Heterogeneity of Ewing Sarcoma at Single-Cell Resolution.
Aynaud MM; Mirabeau O; Gruel N; Grossetête S; Boeva V; Durand S; Surdez D; Saulnier O; Zaïdi S; Gribkova S; Fouché A; Kairov U; Raynal V; Tirode F; Grünewald TGP; Bohec M; Baulande S; Janoueix-Lerosey I; Vert JP; Barillot E; Delattre O; Zinovyev A
Cell Rep; 2020 Feb; 30(6):1767-1779.e6. PubMed ID: 32049009
[TBL] [Abstract][Full Text] [Related]
40. Linking germline and somatic variation in Ewing sarcoma.
Gomez NC; Davis IJ
Nat Genet; 2015 Sep; 47(9):964-5. PubMed ID: 26313223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
